Abstract
T cell exhaustion is a hallmark of cancer and persistent infections, marked by inhibitory receptor upregulation, diminished cytokine secretion, and impaired cytolytic activity. Terminally exhausted T cells are steadily replenished by a precursor population (Tpex), but the metabolic principles governing Tpex maintenance and the regulatory circuits that control their exhaustion remain incompletely understood. Using a combination of gene-deficient mice, single-cell transcriptomics, and metabolomic analyses, we show that mitochondrial insufficiency is a cell-intrinsic trigger that initiates the functional exhaustion of T cells. At the molecular level, we find that mitochondrial dysfunction causes redox stress, which inhibits the proteasomal degradation of hypoxia-inducible factor 1α (HIF-1α) and promotes the transcriptional and metabolic reprogramming of Tpex cells into terminally exhausted T cells. Our findings also bear clinical significance, as metabolic engineering of chimeric antigen receptor (CAR) T cells is a promising strategy to enhance the stemness and functionality of Tpex cells for cancer immunotherapy.
| Original language | English |
|---|---|
| Article number | 6858 |
| Journal | Nature Communications |
| Volume | 14 |
| Issue number | 1 |
| ISSN | 1751-8628 |
| DOIs | |
| Publication status | Published - 12.2023 |
Funding
We thank Jeffery D. Molkentin (Cincinnati Children’s Hospital Medical Center, OH, USA), Anjana Rao (La Jolla Institute for Immunology, CA, USA) and Tobias Bald (University Hospital Bonn, Germany) for providing Slc25a3 mice, CAR constructs and MC38 cells, respectively. This work was funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) SFB-TR 124/3 (“FungiNet”), project number 210879364, SFB 1526/1 (“PANTAU”), project number 454193335, SFB 1583/1 (“DECIDE”), project number 492620490 and individual grants VA882/2-1 and VA882/3-2 (to M.V.). Further funding was provided by the SFB 1525/1 (“Cardio-Immune-Interfaces”), project number 453989101 (to M.V., A.Z., W.K., G.G. and J.D.) and SFB-TR 338/1 (“LETSimmun”), project number 452881907 (to. M.V. G.G., W.K., S.T. and S.K.). Our study was supported by the Interdisciplinary Center for Clinical Research (supporting the Core Units FACS and SysMed) and by the Bavarian ministry of economic affairs, Regional Development and energy within the project “Single Cell Analysis in personalized medicine” at the Helmholtz-Institute for RNA-based Infection Research (HIRI). We would like to thank Camila Takeno Cologna, Wesley Vermaelen, Anton Willems (VIB Metabolomics Expertise Center), Thorsten Bischler (IZKF Würzburg), and Fabian Imdahl (HIRI) for excellent technical assistance. fl/fl We thank Jeffery D. Molkentin (Cincinnati Children’s Hospital Medical Center, OH, USA), Anjana Rao (La Jolla Institute for Immunology, CA, USA) and Tobias Bald (University Hospital Bonn, Germany) for providing Slc25a3fl/flmice, CAR constructs and MC38 cells, respectively. This work was funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) SFB-TR 124/3 (“FungiNet”), project number 210879364, SFB 1526/1 (“PANTAU”), project number 454193335, SFB 1583/1 (“DECIDE”), project number 492620490 and individual grants VA882/2-1 and VA882/3-2 (to M.V.). Further funding was provided by the SFB 1525/1 (“Cardio-Immune-Interfaces”), project number 453989101 (to M.V., A.Z., W.K., G.G. and J.D.) and SFB-TR 338/1 (“LETSimmun”), project number 452881907 (to. M.V. G.G., W.K., S.T. and S.K.). Our study was supported by the Interdisciplinary Center for Clinical Research (supporting the Core Units FACS and SysMed) and by the Bavarian ministry of economic affairs, Regional Development and energy within the project “Single Cell Analysis in personalized medicine” at the Helmholtz-Institute for RNA-based Infection Research (HIRI). We would like to thank Camila Takeno Cologna, Wesley Vermaelen, Anton Willems (VIB Metabolomics Expertise Center), Thorsten Bischler (IZKF Würzburg), and Fabian Imdahl (HIRI) for excellent technical assistance.
Research Areas and Centers
- Academic Focus: Center for Infection and Inflammation Research (ZIEL)
- Centers: Center for Research on Inflammation of the Skin (CRIS)
DFG Research Classification Scheme
- 2.22-19 Dermatology
- 2.21-05 Immunology
Fingerprint
Dive into the research topics of 'Mitochondrial dysfunction promotes the transition of precursor to terminally exhausted T cells through HIF-1α-mediated glycolytic reprogramming'. Together they form a unique fingerprint.Projects
- 1 Active
-
CRC 1526, PANTAU: Pathomechanisms of Antibody-mediated Autoimmunity
Sadik, C. (Speaker, Coordinator), Zillikens, D. (Speaker, Coordinator), Scheffold, A. (Principal Investigator (PI)), Schmidt, E. (Principal Investigator (PI)), Heine, G. (Principal Investigator (PI)), Manz, R. (Principal Investigator (PI)), Köhl, J. (Principal Investigator (PI)), Ludwig, R. (Principal Investigator (PI)), Peipp, M. (Principal Investigator (PI)), Hammers, M. C. (Principal Investigator (PI)), Verschoor, A. (Principal Investigator (PI)), Karsten, C. (Principal Investigator (PI)), Nimmerjahn, F. (Principal Investigator (PI)), Hutloff, A. (Principal Investigator (PI)), Ibrahim, S. (Principal Investigator (PI)), Wettschureck, N. (Principal Investigator (PI)), Bieber, K. (Principal Investigator (PI)), Schilf, P. (Principal Investigator (PI)), Vaeth, M. (Principal Investigator (PI)), Hirose, M. (Principal Investigator (PI)), Vaeth, M. (Principal Investigator (PI)), Baines, J. F. (Principal Investigator (PI)), Bacher, P. (Principal Investigator (PI)), Hoffmann, M. (Principal Investigator (PI)), Busch, H. S. (Principal Investigator (PI)), Höppner, M. (Principal Investigator (PI)), Becker, M. (Principal Investigator (PI)), Holtsche, M. M. (Principal Investigator (PI)), Fähnrich, A. (Principal Investigator (PI)), Szymczak, S. (Principal Investigator (PI)), Murthy, S. (Principal Investigator (PI)) & Lux, A. (Principal Investigator (PI))
01.01.22 → …
Project: DFG Joint Research › DFG Collaborative Research Centers (CRC)
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver